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Background and objectives: Exacerbations are important outcomes in COPD both from a 
clinical and an economic perspective. Most studies investigating predictors of exacerbations were 
performed in COPD patients participating in pharmacological clinical trials who usually have 
moderate to severe airflow obstruction. This study was aimed to investigate whether predictors 
of COPD exacerbations depend on the COPD population studied.
Methods: A network of COPD health economic modelers used data from five COPD data 
sources – two population-based studies (COPDGene® and The Obstructive Lung Disease in 
Norrbotten), one primary care study (RECODE), and two studies in secondary care (Evaluation 
of COPD Longitudinally to Identify Predictive Surrogate Endpoint and UPLIFT) – to estimate 
and validate several prediction models for total and severe exacerbations (= hospitalization). The 
models differed in terms of predictors (depending on availability) and type of model.
Results: FEV
1
% predicted and previous exacerbations were significant predictors of total 
exacerbations in all five data sources. Disease-specific quality of life and gender were predic-
tors in four out of four and three out of five data sources, respectively. Age was significant 
only in the two studies including secondary care patients. Other significant predictors of total 
exacerbations available in one database were: presence of cough and wheeze, pack-years, 6-min 
walking distance, inhaled corticosteroid use, and oxygen saturation. Predictors of severe exac-
erbations were in general the same as for total exacerbations, but in addition low body mass 
index, cardiovascular disease, and emphysema were significant predictors of hospitalization 
for an exacerbation in secondary care patients.
Conclusions: FEV
1
% predicted, previous exacerbations, and disease-specific quality of life 
were predictors of exacerbations in patients regardless of their COPD severity, while age, low 
body mass index, cardiovascular disease, and emphysema seem to be predictors in secondary 
care patients only.
Keywords: COPD, exacerbations, modeling, hospitalizations, validation
Introduction
It is well known that the progression of COPD may be accompanied by exacerbations, 
that is, an acute worsening of symptoms. Exacerbations are associated with an accel-
erated decline in lung function,1,2 increase in mortality,3,4 significant impairment of 
health-related quality of life,5–7 and increased health care utilization and associated 
costs.8–10 Consequently, reducing exacerbations is one of the most important treatment 
goals in COPD from both a clinical and an economic perspective.11,12 Because not all 
patients experience exacerbations, identification of patients who are at high risk of 
exacerbations is important to use treatment options in an efficient way.
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Health economic decision models for COPD are used for 
evaluating long-term effectiveness and cost-effectiveness of 
treatment options for COPD. Accurate and precise estimation 
of the exacerbation risk in these models is very important 
because exacerbations are associated with high health care 
costs and therefore strongly influence the cost outcomes of 
the models. However, most of the currently available cost-
effectiveness models include an exacerbation risk specified 
by degree of airflow obstruction13 only and they are not able to 
distinguish high-risk patients based on other relevant predic-
tors, such as previous exacerbations.14 Therefore, the focus 
of the Fourth Annual Meeting of the International COPD 
Health Economic Modelling Network in 2015 was to develop 
prediction models for exacerbations including several rel-
evant patient and disease characteristics as predictors.
Most of the previously published studies investigating 
predictors of exacerbations were done in COPD patients 
participating in pharmacological clinical trials who usually 
have moderate to severe airflow obstruction.14–19 A few 
studies were done in primary care patients with less severe 
COPD.20–22 Because the studies included different candidate 
predictors or used different definitions for predictors, it is dif-
ficult to conclude whether predictors of exacerbations differ 
between patient populations with varying disease severity.
The aim of the current study was to estimate prediction 
models for the total number of exacerbations and severe 
exacerbations using five large sources of patient-level data and 
compare the estimated models between patient populations.
Methods
Procedure
Since 2011, a worldwide network of people involved in 
health economic modeling for COPD (ie, COPD modeling 
teams, employees of pharmaceutical companies interested in 
COPD modeling, clinicians, health economists, and epidemi-
ologists) gathered together for three one-day meetings with 
the aim to discuss and compare the different available COPD 
models and share best practices about COPD modeling.13,23 
In May 2015 participants in this COPD modeling network 
were contacted to explore their interest in participating in a 
modeling exercise for the fourth COPD modeling meeting. 
To participate in this so-called modeling challenge, partici-
pants needed to have access to a database with patient-level 
data with the following characteristics: 1) a minimum of 
about 500 patients, 2) follow-up of at least 1 year, 3) mod-
erate and severe exacerbations measured, and 4) several 
demographic and clinical patient characteristics available. 
For the first part of the challenge, participants were asked 
to estimate several pre-specified prediction models includ-
ing one or multiple predictors and using different statistical 
methods. In the second part of the challenge, the estimated 
prediction models were validated. A structured Microsoft 
Excel file was used to collect the results in a uniform way 
before the meeting. During the meeting the results were 
presented and discussed.
sources of data
Data from five different data sources were used for the 
modeling challenge: two population-based studies – the 
COPDGene® study and the Obstructive Lung Disease in 
Norrbotten (OLIN) study – one study in primary care patients – 
the RECODE trial – and two studies including secondary 
care patients – the Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints (ECLIPSE) study 
and the UPLIFT trial.24–28 The COPDGene study is a multi-
institutional study of past and current smokers to identify the 
genetic factors that control the development and progression 
of COPD. The primary analysis cohort dataset consists of 
about 10,300 smokers in the general population. For this 
modeling challenge a subgroup of 3,756 patients with a 
diagnosis of COPD were included, who were on average 
followed for 4.7 years.24 The OLIN study is a population-
based screening study for COPD in the general population in 
northern Sweden. The prevalence of more severe patients is 
therefore low, reflective of actual prevalence. For the current 
study, the data of patients with a COPD diagnosis enrolled in 
2005 and their follow-up data for 2006 were used. Observa-
tions of severe exacerbations were scarce, and therefore no 
separate analysis for severe exacerbations was performed.25 
The RECODE trial was a 2-year cluster-randomized trial in 
which 20 primary care teams were randomized to an inter-
vention group of general practitioner practices that imple-
mented an integrated care program for COPD and 20 teams 
were randomized to a usual care group.26 The ECLIPSE 
study was a non-interventional, longitudinal prospective 
3-year study in COPD patients aged 40–75 years with a 
baseline post-bronchodilator forced expiratory volume in 
1 s (FEV
1
)% predicted ,80%, baseline post-bronchodilator 
FEV
1
/forced vital capacity (FVC) ,0.7, and a smoking 
history of at least 10 pack-years.27 The UPLIFT trial was 
a 4-year randomized controlled trial comparing tiotropium 
versus placebo in patients with a diagnosis of COPD (FEV
1
/
FVC ,70%), age $40 years, .10 pack-years, and an FEV
1
% 
predicted ,70%.28 The study protocols of all five studies 
were approved by the relevant ethics and review boards of 
the participating centers.
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exacerbations
Participants were asked to use the following definition for 
an exacerbation: a moderate exacerbation was defined as 
an increase in symptoms requiring a visit to a health care 
provider and a course of antibiotics and/or oral steroids. 
A severe exacerbation was defined as an exacerbation requir-
ing hospitalization.
Predictions models
Prediction models were estimated separately for total and 
severe exacerbations. For each data source, a randomly 
selected 67% of the patient population was used to estimate 
the prediction models, while the remaining 33% was set aside 
for validation purposes.
Five different prediction models for the annual exacerba-
tion rate were estimated using negative binomial regression29 
with the natural logarithm of the total time at risk in years 
as offset variable and the number of exacerbations as out-
come. The time at risk was defined as total time in the study, 
which was shorter than the duration of the study for patients 
who dropped out or died before the end of the study. The 
estimated regression coefficients for the predictors were 
transformed into incidence rate ratio (IRR) by taking the 
exponent of the estimated coefficient. All variables included 
as predictors were measured at baseline. The five different 
prediction models varied in the number of predictors and 
the type of model used. The first two prediction models 
were pre-specified and included the same predictors for 
all data sources. For the first model, groups were asked to 
estimate a model including the predictors FEV
1
% predicted 
at baseline and treatment for the two trials, that is, RECODE 
and UPLIFT. For the second model, groups were asked to 
include the same patient and clinical parameters as in a 
previously published prediction model by Briggs et al,16 
that is, sex, age, FEV
1
% predicted, total number of (severe) 
exacerbations in the year prior to baseline (depending on the 
outcome used), disease-specific quality of life, body mass 
index (BMI) ,20 kg/m2, history of cardiovascular disease 
and treatment, if applicable. For model 3, groups were asked 
to include all patient and clinical parameters from model 2 
plus other possible relevant variables available in the data 
source to be chosen by the modeling team, for example, 
dyspnea, COPD duration, and other comorbidities. The lat-
ter predictors were different for the different data sources. 
In the fourth model, the impact of using a different statistical 
method was explored. Model 4 included the same predictors 
as model 3 but used a zero-inflated binomial regression model 
with an indicator of previous exacerbations at baseline in 
the zero-model. With model 5, the impact of two different 
definitions for previous exacerbations was assessed using 
multilevel negative binomial regression. Model 5 included 
the same predictors as model 3 and had two variants: one 
using exacerbations prior to baseline as predictor (model 5A) 
and one using exacerbations in the previous period as pre-
dictor (model 5B; using the exacerbation rate in Year 1 to 
predict the rate in Year 2, the rate in Year 2 to predict the 
rate in Year 3, etc.).
Validation
For the validation part, participants were asked to use the 
remaining 33% of the population in their data source. First 
the mean observed exacerbation rate was calculated using 
the observation time of each patient as a weight, that is, 
patients with a longer follow-up have a higher weight than 
patients with a short follow-up. In addition, the predicted 
exacerbation rate for each patient based on each of the five 
different models was calculated by filling in the estimated 
regression equations for each individual patient. Thereafter, 
the mean predicted exacerbation rate over all patients was 
determined. Finally, absolute errors were calculated as the 
absolute difference between the individual observed and 
predicted exacerbation rates for each patient. The mean 
absolute error (MAE) between the observed and predicted 
rates was calculated using the observation time of the indi-
vidual patient as a weight. If the MAE is small, the observed 
and predicted exacerbation rates are fairly similar. If the 
MAE is large, the predicted rate for patients is substantially 
different from the observed rate.
Results
Characteristics of the patients included in the five different 
participating data sources are shown in Table 1. For the 
ECLIPSE and UPLIFT studies, the mean FEV
1
% predicted 
was about 48%, and more than half of the patients had severe 
to very severe airflow obstruction. Patients in the population-
based OLIN study had the highest mean FEV
1
% predicted 
(76%). In this data source, only 7% of the patients were 
classified as having severe or very severe airflow obstruction. 
Mean FEV
1
% predicted of the population-based COPDGene 
study and the primary care-based RECODE study were 
57% and 68%, respectively.
Figure 1 shows the percentage of patients with at least 
one exacerbation during follow-up. The lowest percentages 
were found for the OLIN study with a follow-up duration 
of 1 year. Percentages in ECLIPSE were highest, although 
UPLIFT had a longer follow-up.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
80
.1
01
.8
8.
13
8 
on
 1
5-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3186
hoogendoorn et al
Figure 2 shows the mean exacerbation rates during 
follow-up for all five data sources. The number of exacerba-
tions per patient-year ranged from 0.18 in the OLIN study to 
1.20 in the ECLIPSE study. The number of severe exacer-
bations per patient-year varied between 0.02 for OLIN and 
0.26 for ECLIPSE.
Results of prediction model 1 including only FEV
1
% 
predicted and treatment, if applicable, showed that for 
all five data sources FEV
1
% was a significant predictor 
of total and severe exacerbations. Model 2, that is, with 
addition of sex, age, exacerbations prior to baseline, 
disease-specific quality of life, low BMI, and history of 
cardiovascular disease showed that besides FEV
1
% pre-
dicted, exacerbations prior to baseline and disease-specific 
quality of life were important predictors of exacerbations. 
Results of model 3, which also allowed inclusion of 
other data source-specific variables besides the fixed set 
of predictors of model 2, are shown in Table 2 for total 
exacerbations and Table 3 for severe exacerbations. Both 
tables show IRRs, while more detailed information on 
coefficients, standard errors, and p-values for the different 
predictors are presented in the Supplementary materials 
(Tables S1–S5).
FEV
1
% predicted and exacerbations prior to baseline 
were the most important significant predictors of total 
exacerbations in all five data sources (p-values ,0.001) 
(Table 2). Disease-specific quality of life, that is, St George’s 
Respiratory Questionnaire (SGRQ) total score was also an 
important significant predictor in all four databases for which 
it was available. For the other significant predictors, there 
was more variation in p-values. Sex was a predictor in three 
out of five databases with female patients having higher 
Table 1 Baseline characteristics# of the patients in the five data sources, data are mean or %
COPDGene24 OLIN25 RECODE26 ECLIPSE27 UPLIFT28
n 3,756 449 1,086 2,164 5,799
Male (%) 44 60 46 65 75
age 64 63 68 63 64
Post FeV1% predicted 57.3 75.8 67.8 48.3 47.6
gOlD stages based on FeV1%
Mild 16 41 24 0 0
Moderate 41 53 53 44 46
severe 26 6 19 42 45
Very severe 12 1 3 14 9
Smoker (%) 37 na 37 36 30
BMI ,20 (%) 5 3 na 11 11
History of cardiovascular disease (%) 9.8 25 16 33 52
sgrQ total score 36 na 36 50 46
exacerbations in the year prior to baseline
Total exacerbations 0.64 0.30 0.37 1.21 0.85
severe exacerbations 0.18 0.02 0.02* 0.22 0.25
Notes: #Only characteristics that were available in all or almost all databases were included in this table. *In 3 months.
Abbreviations: BMI, body mass index; eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; FeV1, forced expiratory volume in 1 
second; gOlD, global Initiative for chronic Obstructive lung Disease; na, not available; OlIn, Obstructive lung Disease in norrbotten; sgrQ, st george’s respiratory 
Questionnaire.
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Figure 1 Percentage of patients with at least one (severe) exacerbation during 
follow-up with the duration of follow-up presented in brackets.
Abbreviations: eClIPse, evaluation of COPD longitudinally to Identify Predictive 
surrogate endpoints; OlIn, Obstructive lung Disease in norrbotten.
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Figure 2 Mean annual total and severe exacerbation rates during follow-up. (rates 
are calculated as the sum of exacerbations over all patients divided by the sum of 
follow-up time to correct for patients with a short follow-up time.)
Abbreviations: eClIPse, evaluation of COPD longitudinally to Identify Predictive 
surrogate endpoints; OlIn, Obstructive lung Disease in norrbotten.
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rates. Age was significant only in the two studies including 
secondary care patients, ECLIPSE and UPLIFT. Results for 
current smoking in two studies showed that current smokers 
had a lower incidence rate for exacerbations than former 
smokers, while two other studies found a non-significant 
higher rate for current smokers. Other predictors found to 
be predictive of a higher exacerbation rate available in a 
single data source were: increasing number of pack-years, 
presence of cough and wheeze, 6-min walking test, and 
inhaled corticosteroid (ICS) use at baseline. An increase in 
resting oxygen was found to be associated with a decrease 
in exacerbation rate in COPDGene.
Predictors of the number of severe exacerbations were 
in general the same as of the total number of exacerbations, 
but in addition low BMI, history of cardiovascular disease, 
presence of emphysema, and current smoking were found to 
be predictors in secondary care COPD patients (ECLIPSE 
and/or UPLIFT). Contrary to the total number of exacerba-
tions, sex was a significant predictor of the number of severe 
exacerbations in only one database (COPDGene).
Results for model 4 using a zero-inflated negative bino-
mial regression model instead of regular negative binomial 
regression showed that using this type of model is relevant 
only when the proportion of patients without any exacerba-
tions is very high. Only for the OLIN study in which 86% 
of patients had no exacerbations during follow-up, the coef-
ficient for the zero-inflated model parameter was significant. 
Using exacerbations in the previous period as predictor 
instead of using exacerbations in the year prior to baseline 
(model 5) did not seem to improve the model fit much. Only 
for UPLIFT, the study with the longest follow-up period, a 
slight improvement in the model fit was observed.
Validation results for the different models are shown in 
Table 4. In general, for total number of exacerbations the 
mean annual predicted rates were somewhat higher than 
the mean observed rates, but the MAEs of the models were 
large. Compared to the model including FEV
1
 only (model 1), 
the MAEs for the models including more patient character-
istics tended to be slightly lower indicating that the models 
with more patient characteristics resulted in slightly better 
Table 2 Prediction models for total exacerbations including a fixed set of predictors and other database-specific predictors (results 
from multivariate analysis)
IRRs#
COPDGene24 OLIN25 RECODE26 ECLIPSE27 UPLIFT28
Fixed set of predictors
sex (1= female) 1.23** 2.86* 1.20 1.31*** 1.09
age (years) 1.00 1.00 1.00 1.01* 1.01***
FeV1% predicted (in %) 0.99*** 0.96** 0.98*** 0.99*** 0.99***
number of exacerbations prior to baseline 1.75*** 1.49*** 1.58*** 1.38*** 1.25***
BMI ,20 kg/m2 (1= yes) 0.98 1.65 – 1.09 1.20**
history of cardiovascular disease (1= yes) 1.07 1.13 1.06 0.98 0.99
sgrQ total score at baseline (in points) 1.01*** – 1.02** 1.01*** 1.01***
Treatment group in trial (1= yes) – – 1.08 – 0.83***
Other database-specific predictors
smoker (1= yes, 0= former) 0.81** – 1.07 0.88* 1.05
Pack-years – – – – 1.002**
Time since diagnosis (years) – – – – 1.005
Diagnosis of emphysema (1= yes) – – – – 0.97
Cough (1= yes) 1.16* – – – –
Wheeze (1= yes) 1.37*** – – – –
MrC dyspnea – – 0.98 1.03 –
Charlson comorbidity index – – 0.98 – 0.98
Other comorbidities (1= yes) – – – 1.00 –
6-min walking test (m) – – – 1.001*** –
Physical activity IPaQ (1= low) – – 0.81 – –
ICs at baseline (1= yes) – – – – 1.30***
resting O2 saturation (in %) 0.97** – – – –
Fibrinogen (mg/dl) – – – 1.00 –
Notes: #ratios above 1 indicating an increased risk and ratios below 1 indicating a reduced risk for exacerbations. *p,0.05. **p,0.01. ***p,0.001.
Abbreviations: BMI, body mass index; eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; FeV1, forced expiratory volume in 1 second; 
ICs, inhaled corticosteroid; IPaQ, International Physical activity Questionnaire; Irr, incidence rate ratio; MrC, Medical research Council; OlIn, Obstructive lung Disease 
in norrbotten; sgrQ, st george’s respiratory Questionnaire.
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predictions on the individual level. For severe exacerbations, 
the mean annual predicted rates were higher than the mean 
observed rates for all models in all databases. Contrary to 
the results for total exacerbations, the MAEs did not seem 
to decrease when more patient and clinical parameters were 
added to the models.
Discussion
This study aimed to estimate prediction models for total 
and severe exacerbations using different COPD patient 
populations to explore whether predictors of exacerbations 
are different in patient populations with a different disease 
severity. Results showed that FEV
1
% predicted and previ-
ous exacerbations were significant predictors in all data 
sources regardless of the severity of the COPD population. 
The importance of previous exacerbations as predictor of 
future exacerbations was already well known from studies 
mainly performed in secondary care patients with severe 
COPD.14–17,19 The current study showed that the number of 
previous exacerbations is also a good predictor in patients 
with less severe airflow obstruction. Even if more than 40% 
of the patients were classified as having mild obstruction 
(OLIN studies), previous exacerbations were found to be a 
strong predictor. The SGRQ total score was also found to be 
an important significant predictor of exacerbations in four 
out of four data sources, which was also in line with three 
previously performed studies in severe COPD patients.14,16,17 
One study in COPD patients with less severe airflow obstruc-
tion reported an association between exacerbation risk and 
responses to the clinical COPD questionnaire.30 Previous 
studies already showed that patients with frequent exacerba-
tions have a lower health-related quality of life, but in the 
current study health status was found to be an independent 
predictor of new exacerbations after adjusting for previous 
exacerbations. Additional analyses using the UPLIFT and 
RECODE data showed that especially the SGRQ symptom 
sub-score and the SGRQ impact sub-score were predictive of 
future exacerbation risk, while the SGRQ activity sub-score 
was not found to be a significant predictor.
Female gender was found to be a predictor of total 
exacerbations in three out of five data sources. In the UPLIFT 
trial, female gender was borderline significant (p=0.07). 
Table 3 Prediction models for severe exacerbations including a fixed set of predictors and other database-specific predictors (results 
from multivariate analysis)
IRRs#
COPDGene24 RECODE26 ECLIPSE27 UPLIFT28
Fixed set of predictors
sex (1= female) 1.22* 0.64 1.05 1.02
age (years) 1.00 1.02 1.03** 1.03***
FeV1% predicted (in %) 0.99*** 0.98* 0.98*** 0.97***
number of severe exacerbations prior to baseline 2.15*** 5.19* 1.99*** 1.68***
BMI ,20 (1= yes) 1.30 – 1.44* 1.83***
history of cardiovascular disease (1= yes) 1.26 0.64 1.38** 1.11
sgrQ total score at baseline (in points) 1.02*** 1.03** 1.02*** 1.01***
Treatment group in trial (1= yes) – 0.96 – 0.86*
Other database-specific predictors
smoker (1= yes, 0= former) 0.99 1.23 1.11 1.23*
Pack-years – – – 1.00
Time since diagnosis (years) – – – 1.01
Diagnosis of emphysema (1= yes) – – – 1.18*
Cough (1= yes) 1.01 – – –
Wheeze (1= yes) 1.34** – – –
MrC dyspnea – 1.14 0.93 –
Charlson comorbidity index – 1.03 – 1.03
Other comorbidities (1= yes) – – 0.87 –
6-min walking test (meters) – – 1.00 –
Physical activity IPaQ (1= low) – 0.98 – –
ICs at baseline (1= yes) – – – 1.23**
resting O2 saturation 1.00 – – –
Fibrinogen (mg/dl) – – 1.00 –
Notes: #ratios above 1 indicating an increased risk and ratios below 1 indicating a reduced risk for exacerbations. *p,0.05. **p,0.01. ***p,0.001.
Abbreviations: BMI, body mass index; eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; FeV1, forced expiratory volume in 1 second; 
ICs, inhaled corticosteroid; IPaQ, International Physical activity Questionnaire; Irr, incidence rate ratio; MrC, Medical research Council; sgrQ, st george’s respiratory 
Questionnaire.
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For severe exacerbations, only one data source found a sig-
nificant impact of gender. Seven out of nine studies found 
in the literature confirmed the finding that female patients 
have a higher number of total exacerbations.15–17,19,21,22,31 
Little is known about the reason why women seem to have 
more exacerbations. It may be related to physiological or 
treatment-related factors,32 but it might also be explained by 
the health care-based definition used to identify exacerba-
tions and the fact that women tend to seek health care more 
often.33 In the current study, age was a predictor only in the 
two studies including patients with severe airflow obstruc-
tion. This finding seems to be in line with the literature that 
showed an association between age and exacerbations in five 
out of seven studies including patients with severe airflow 
obstruction,14–19,31 while this association was found in only 
one out of five studies including less severe patients.20–22,30,34 
In none of the currently explored data sources, history of 
cardiovascular disease was a predictor of total exacerba-
tions, while several studies in patients with less severe 
airflow obstruction did find an association.20–22,34 Predictors 
of severe exacerbations were in general the same as of total 
exacerbations. Due to the definition used, predictors of severe 
exacerbations actually need to be interpreted as predictors of 
hospitalization for an exacerbation. The results showed that 
patients with mainly severe airflow obstruction and additional 
risk factors, that is, history of cardiovascular disease, low 
BMI, current smoking, and presence of emphysema, are more 
likely to be hospitalized, which is as expected.
Model validation results showed that the models pre-
dicted exacerbation rates quite well on an average level, 
because the mean predicted rates were comparable although 
somewhat higher than the mean observed rate. However, the 
MAEs of the models were large indicating that the models 
were predicting less well on an individual level. MAEs seem 
to decrease from model 1 to model 3, showing that adding 
more patient and clinical parameters seemed to improve 
predictions on the individual level slightly.
Based on the results of the prediction models, it is difficult 
to come up with interventions or treatment advice to reduce 
the risk of an exacerbation. Some factors, such as gender and 
age, cannot be influenced, while others such as FEV
1
 and 
SGRQ total score can be influenced by treatment. They are 
well recognized as important treatment goals, but it is a chal-
lenge to change them substantially within a short time period. 
Table 4 Model validation results for total and severe exacerbations: weighted mean observed annual exacerbation rate, mean predicted 
annual exacerbation rates, and weighted Maes
COPDGene24 OLIN25 RECODE26 ECLIPSE27 UPLIFT28
Rate MAE Rate MAE Rate MAE Rate MAE Rate MAE
Total exacerbations
Weighted mean observed rate 0.61 – 0.15 – 0.51 – 1.22 – 0.79 –
Predicted rates
Model 1: FeV1 only 0.65 0.63 0.18 0.28 0.51 0.62 1.25 1.05 0.83 0.64
Model 2: fixed set of predictors 0.65 0.58 0.25 0.28 0.57 0.56 1.31 0.80 0.89 0.62
Model 3: model 2 plus data 
source-specific predictors
0.66 0.58 na na 0.57 0.56 1.28 0.81 0.89 0.62
Model 4: zero-inflated model 0.64 0.58 0.20 0.22 0.66 0.60 1.24 0.77 0.91 0.62
Model 5a: exacerbations in the 
year prior to baseline
na na na na 0.60 0.64 1.09 0.94 0.82 0.84
Model 5B: exacerbations in the 
previous period 
na na na na 0.56 0.61 1.23 0.95 0.83 0.82
Severe exacerbations
Weighted mean observed rate 0.17 – 0.02 – 0.07 – 0.27 – 0.15 –
Predicted rates
Model 1: FeV1 only 0.22 0.25 na na 0.07 0.13 0.28 0.34 0.18 0.22
Model 2: fixed set of predictors 0.22 0.22 na na 0.17 0.19 0.34 0.44 0.40 0.34
Model 3: model 2 plus data 
source-specific predictors
0.22 0.22 na na 0.18 0.21 0.33 0.44 0.41 0.35
Model 4: zero-inflated model 0.21 0.22 na na 0.24 0.23 0.30 0.41 0.34 0.30
Model 5a: exacerbations in the 
year prior to baseline 
na na na na 0.14 0.17 0.19 0.34 0.27 0.34
Model 5B: exacerbations in the 
previous period 
na na – – 0.09 0.13 0.19 0.35 0.24 0.32
Abbreviations: eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; FeV1, forced expiratory volume in 1 second; Maes, mean absolute 
errors; na, not available; MrC, Medical research Council; OlIn, Obstructive lung Disease in norrbotten.
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Therefore, results of the current study mainly create aware-
ness about which type of patients are more likely to experi-
ence exacerbations and hence should be closely monitored. 
It further stresses on the need for new, more targeted predic-
tors of exacerbations like biomarkers, which were unfortu-
nately not present in the available databases.
A strength of the current study is that exactly the same 
methods were used in five different data sources. By using 
the same type of model with a partially fixed set of predictors 
and ensuring variables were defined in the same way in all 
data sources, the comparability of the results between the 
different data sources, and hence populations, was improved 
as much as possible.
A limitation of the study is that there are slight dif-
ferences in the way exacerbations are defined in the five 
available databases. All databases included treatment with 
antibiotics or oral corticosteroids in the definition. But in 
some databases patients needed to have an increase in respi-
ratory symptoms lasting for a pre-specified number of days, 
while in other databases an unscheduled visit to a health care 
provider was a requirement. Next to that, the studies were 
performed in different countries with differences in treat-
ment patterns and access to health care. These differences 
in the definitions and health care settings mainly affected the 
observed exacerbation rates and most likely not the analyses 
of predictors. Heterogeneity in the definition of a severe 
exacerbation might have had more impact on the results. 
Because the different studies were performed in different 
health care settings, the likelihood to be hospitalized for an 
exacerbation may also vary substantially between patients. 
This may partly explain why the predictors of total and 
severe exacerbations are very similar. Despite this, we found 
some new predictors of severe exacerbations especially in 
secondary care patients.
Although a large number of different predictors of exac-
erbations were included in the different regression models, 
not all potential relevant predictors were included in the 
analyses. Especially, information on biomarkers is lacking 
in the current study. This was mainly because the majority 
of studies were performed almost 10 years ago, when data on 
biomarkers were not yet collected as often as they are nowa-
days. Using older data might have had an impact on the abso-
lute exacerbation rates observed in the different databases. 
Because several new treatment options became available in 
the last decade, exacerbation rates in more recent trials might 
be lower. However, a lower rate is unlikely to greatly influ-
ence the variables that were found to be predictors.
In conclusion, FEV
1
% predicted, previous exacer-
bations, and disease-specific quality of life were identified 
as predictors of the total number of exacerbations in COPD 
patients regardless of their COPD severity. In secondary care 
patients age was found to be a predictor of total exacerba-
tions, and low BMI, history of cardiovascular disease, and 
presence of emphysema were predictors of hospitalization 
for an exacerbation.
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Supplementary materials
Table S1 Prediction models for total number of exacerbations and number of severe exacerbations using COPDGene data: coefficients 
(se) and p-values*
COPDGene1
Total exacerbations Severe exacerbations
Coefficient (SE) p-value Coefficient (SE) p-value
Intercept 2.06 (1.06) 0.052 −1.68 (1.42) 0.24
sex (1= female) 0.21 (0.07) 0.001 0.20 (0.09) 0.03
age (years) −0.0012 (0.005) 0.79 −0.0037 (0.006) 0.54
FeV1% predicted (in %) −0.011 (0.002) ,0.001 −0.015 (0.002) ,0.001
number of exacerbations prior to baseline – – 0.77 (0.11)# ,0.001
One exacerbation 0.56 (0.08) ,0.001 – –
Two exacerbations 0.67 (0.12) ,0.001 – –
Three exacerbations 0.81 (0.17) ,0.001 – –
Four exacerbations 0.67 (0.23) 0.004 – –
Five exacerbations 0.52 (0.43) 0.23 – –
six or more exacerbations 0.83 (0.24) ,0.001 – –
BMI ,20 kg/m2 (1= yes) −0.020 (0.13) 0.88 0.26 (0.17) 0.14
history of cardiovascular disease (1= yes) 0.071 (0.11) 0.51 0.23 (0.14) 0.10
sgrQ total score at baseline (in points) 0.015 (0.002) ,0.001 0.023 (0.003) ,0.001
smoker (1= yes, 0= former) −0.22 (0.08) 0.006 −0.014 (0.11) 0.90
Cough (1= yes) 0.15 (0.07) 0.043 0.011 (0.10) 0.91
Wheeze (1= yes) 0.32 (0.08) ,0.001 0.29 (0.11) 0.01
resting O2 saturation (in %) −0.034 (0.01) 0.001 −0.0055 (0.01) 0.69
Notes: #severe exacerbations in the year prior to baseline: yes/no. *Predicted rate can be calculated using the following formula: Predicted rate = e(intercept + value predictor1 * coefficient 
predictor1 + value predictor2 * coefficient predictor2 + ....).
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; sgrQ, st george’s respiratory Questionnaire.
Table S2 Prediction models for total number of exacerbations using OLIN data: coefficients (SE) and p-values*
OLIN2: Total exacerbations
Coefficient (SE) p-value
Intercept −0.76 (2.08) 0.71
sex (1= female) 1.05 (0.43) 0.01
age (years) 0.0076 (0.03) 0.78
FeV1% predicted (in %) −0.039 (0.01) 0.002
number of exacerbations prior to baseline 0.40 (0.10) ,0.001
BMI ,20 kg/m2 (1= yes) 0.42 (0.93) 0.65
history of cardiovascular disease (1= yes) 0.43 (0.56) 0.44
Note: *Predicted rate can be calculated using the following formula: Predicted rate = e(intercept + value predictor1 * coefficient predictor1 + value predictor2 * coefficient predictor2 + ....).
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; OlIn, Obstructive lung Disease in norrbotten.
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Table S3 Prediction models for total number of exacerbations and number of severe exacerbations using RECODE data: coefficients 
(se) and p-values*
RECODE3
Total exacerbations Severe exacerbations
Coefficient (SE) p-value Coefficient (SE) p-value
Intercept −0.93 (0.50) 0.06 −4.34 (1.18) ,0.001
sex (1= female) 0.18 (0.13) 0.17 −0.45 (0.32) 0.16
age (years) 0.0039 (0.006) 0.52 0.018 (0.01) 0.19
FeV1% predicted (in %) −0.016 (0.003) ,0.001 −0.018 (0.008) 0.02
number of exacerbations prior to baseline 0.46 (0.06) ,0.001 1.65 (0.67) 0.01
history of cardiovascular disease (1= yes) 0.057 (0.21) 0.78 −0.44 (0.53) 0.40
sgrQ total score at baseline (in points) 0.018 (0.005) 0.001 0.028 (0.01) 0.008
Treatment group trial (1= yes) 0.072 (0.13) 0.57 −0.038 (0.30) 0.90
smoker (1= yes, 0= former) 0.069 (0.14) 0.64 0.0 (0.31) 0.11
MrC dyspnea −0.023 (0.07) 0.73 0.13 (0.14) 0.38
Charlson comorbidity index −0.020 (0.06) 0.75 0.025 (0.15) 0.87
Physical activity IPaQ (1= low) −0.21 (0.20) 0.28 −0.018 (0.50) 0.97
Note: *Predicted rate can be calculated using the following formula: Predicted rate = e(intercept + value predictor1 * coefficient predictor1 + value predictor2 * coefficient predictor2 + ....).
Abbreviations: FeV1, forced expiratory volume in 1 second; IPaQ, International Physical activity Questionnaire; sgrQ, st george’s respiratory Questionnaire.
Table S4 Prediction models for total number of exacerbations and number of severe exacerbations using ECLIPSE data: coefficients 
(se) and p-values*
ECLIPSE4
Total exacerbations Severe exacerbations
Coefficient (SE) p-value Coefficient (SE) p-value
Intercept −1.32 (0.37) ,0.001 −3.62 (0.79) ,0.001
sex (1= female) 0.27 (0.06) ,0.001 0.049 (0.13) 0.71
age (years) 0.0098 (0.004) 0.02 0.028 (0.009) 0.003
FeV1% predicted (in %) −0.012 (0.002) ,0.001 −0.024 (0.005) ,0.001
number of exacerbations prior to baseline 0.32 (0.02) ,0.001 0.69 (0.09) ,0.001
BMI ,20 kg/m2 (1= yes) 0.085 (0.09) 0.35 0.36 (0.17) 0.04
history of cardiovascular disease (1= yes) −0.020 (0.06) 0.74 0.32 (0.12) 0.009
sgrQ total score at baseline (in points) 0.0083 (0.002) ,0.001 0.017 (0.004) ,0.001
smoker (1= yes, 0= former) −0.12 (0.006) 0.046 0.11 (0.13) 0.40
MrC dyspnea 0.026 (0.07) 0.69 −0.077 (0.14) 0.58
Other comorbidities (1= yes) 0.002 (0.06) 0.97 −0.14 (0.13) 0.31
6-min walking test (m) 0.0009 (0.0003) ,0.001 −0.0002 (0.0006) 0.70
Fibrinogen (mg/dl) 0.0001 (0.0003) 0.77 0.0009 (0.0006) 0.10
Note: *Predicted rate can be calculated using the following formula: Predicted rate = e(intercept + value predictor1 * coefficient predictor1 + value predictor2 * coefficient predictor2 + ....).
Abbreviations: BMI, body mass index; eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; FeV1, forced expiratory volume in 1 second; 
MrC, Medical research Council; sgrQ, st george’s respiratory Questionnaire.
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Table S5 Prediction models for total number of exacerbations and number of severe exacerbations using UPLIFT data: coefficients 
(se) and p-values*
UPLIFT5
Total exacerbations Severe exacerbations
Coefficient (SE) p-value Coefficient (SE) p-value
Intercept −1.17 (0.21) ,0.001 −3.62 (0.39) ,0.001
sex (1= female) 0.082 (0.05) 0.07 0.019 (0.09) 0.83
age (years) 0.011 (0.002) ,0.001 0.031 (0.005) ,0.001
FeV1% predicted (in %) −0.0013 (0.002) ,0.001 −0.032 (0.003) ,0.001
number of exacerbations prior to baseline 0.23 (0.02) ,0.001 0.052 (0.05) ,0.001
BMI ,20 kg/m2 (1= yes) 0.18 (0.06) 0.005 0.61 (0.11) ,0.001
history of cardiovascular disease (1= yes) −0.015 (0.04) 0.73 0.10 (0.08) 0.20
sgrQ total score at baseline (in points) 0.0074 (0.001) ,0.001 0.014 (0.02) ,0.001
Treatment group trial (1= yes) −0.18 (0.04) ,0.001 −0.15 (0.07) 0.04
smoker (1= yes) 0.05 (0.04) 0.26 0.21 (0.08) 0.01
Pack-years 0.002 (0.007) 0.005 0 (0.001) 0.97
Time since diagnosis (years) 0.0047 (0.003) 0.08 0.0068 (0.005) 0.18
Diagnosis of emphysema (1= yes) −0.032 (0.04) 0.42 0.17 (0.08) 0.03
Charlson comorbidity index −0.021 (0.03) 0.40 0.028 (0.05) 0.53
ICs at baseline (1= yes) 0.26 (0.04) ,0.001 0.21 (0.08) 0.008
Note: *Predicted rate can be calculated using the following formula: Predicted rate = e(intercept + value predictor1 * coefficient predictor1 + value predictor2 * coefficient predictor2 + ....).
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; ICs, inhaled corticosteroid; sgrQ, st george’s respiratory Questionnaire.
References
1. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of 
COPD (COPDGene) study design. COPD. 2010;7(1):32–43. 
2. Montnemery P, Adelroth E, Heuman K, et al. Prevalence of obstructive 
lung diseases and respiratory symptoms in southern Sweden. Respir 
Med. 1998;92(12):1337–1345. 
3. Kruis AL, Boland MR, Schoonvelde CH, et al. RECODE: design and 
baseline results of a cluster randomized trial on cost-effectiveness 
of integrated COPD management in primary care. BMC Pulm Med. 
2013;13(1):17. 
4. Vestbo J, Anderson W, Coxson HO, et al; ECLIPSE investigators. Evalu-
ation of COPD longitudinally to identify predictive surrogate end-points 
(ECLIPSE). Eur Respir J. 2008;31(4):869–873. 
5. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design consider-
ations in assessing long-term functional impacts of tiotropium in COPD: 
the UPLIFT trial. COPD. 2004;1(2):303–312
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
80
.1
01
.8
8.
13
8 
on
 1
5-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
